Program
mavacamten
Also written as “Mavacamten” and “MYK-461”.
Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 183 open or running | phase 4since Oct 27, 2023 | Dec 19, 2014 | Dec 13, 2027phase 4 · NCT07004972 |
| LianBio | 20 open or running | phase 3since Dec 13, 2021 | Oct 28, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Dec 19, 2014.
- Apr 5, 2018Phase 2 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT03496168 · 13 enrolled · United States
- Oct 24, 2018Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT03723655 · 314 enrolled · United States, Belgium, Czechia and more
- Apr 7, 2020Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT04349072 · 112 enrolled · United States
- Feb 16, 2021Phase 2 study in Cardiomyopathy, Familial Restrictive, 3Bristol-Myers Squibb · NCT04766892 · 30 enrolled · United States, Canada
- Oct 28, 2021LianBio's first study: phase 1 study in Cardiomyopathy, HypertrophicNew to LianBioLianBio · NCT05135871 · 45 enrolled · China
- Dec 13, 2021Phase 3 study in Cardiomyopathy, HypertrophicLianBio · NCT05174416 · 81 enrolled · China
- Apr 1, 2022Phase 1 study in AnthraxBristol-Myers Squibb · NCT05320094 · 45 enrolled · United States
- May 2, 2022Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05362045 · 158 enrolled · United States
- Jun 7, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05414175 · 38 enrolled · Japan
- Sep 14, 2022Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05582395 · 580 enrolled · United States, Australia, Austria and more
- Jan 31, 2023Phase 1 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT05719805 · 84 enrolled · United States
- Oct 27, 2023Phase 4 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06112743 · 63 enrolled · United States, Argentina, Australia and more
- Feb 2, 2024Phase 3 study in Cardiomyopathy, HypertrophicBristol-Myers Squibb · NCT06253221 · 44 enrolled · United States, Australia, Canada and more
- May 26, 2025Phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972 · 50 enrolled · India
Ahead
- Dec 13, 2027Primary completion: phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyBristol-Myers Squibb · NCT07004972
TargetBeta
“Cardiac myosin inhibitor”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 16 |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 7 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy · India | 4 | Active, not recruiting | Bristol-Myers Squibb | Dec 13, 2027 | 50 |
| NCT06253221Cardiomyopathy, Hypertrophic · United States, Australia, Canada and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Nov 25, 2025 | 44 |
| NCT06112743Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more | 4 | Active, not recruiting | Bristol-Myers Squibb | Jul 16, 2026 | 63 |
| NCT05719805Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Bristol-Myers Squibb | Jul 25, 2023 | 84 |
| NCT05582395Cardiomyopathy, Hypertrophic · United States, Australia, Austria and more | 3 | Terminated | Bristol-Myers Squibb | Mar 6, 2025 | 580 |
| NCT05414175Cardiomyopathy, Hypertrophic · Japan | 3 | Completed | Bristol-Myers Squibb | Nov 27, 2023 | 38 |
| NCT05362045Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Bristol-Myers Squibb | Aug 19, 2022 | 158 |
| NCT05320094Anthrax · United States | 1 | Completed | Bristol-Myers Squibb | Sep 11, 2022 | 45 |
| NCT05174416Cardiomyopathy, Hypertrophic · China | 3 | Completed | LianBio | Mar 6, 2023 | 81 |
| NCT05135871Cardiomyopathy, Hypertrophic · China | 1 | Completed | LianBio | Feb 5, 2022 | 45 |
| NCT04766892Cardiomyopathy, Familial Restrictive, 3 · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Feb 26, 2024 | 30 |
| NCT04349072Cardiomyopathy, Hypertrophic · United States | 3 | Completed | Bristol-Myers Squibb | Feb 7, 2022 | 112 |
| NCT03723655Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more | 3 | Completed | Bristol-Myers Squibb | Jan 16, 2026 | 314 |
| NCT03496168Cardiomyopathy, Hypertrophic · United States | 2 | Completed | Bristol-Myers Squibb | Nov 9, 2023 | 13 |
| NCT03470545Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more | 3 | Completed | Bristol-Myers Squibb | Mar 14, 2020 | 251 |
| NCT03442764Non-obstructive Hypertrophic Cardiomyopathy · United States | 2 | Completed | Bristol-Myers Squibb | Jan 7, 2020 | 59 |
| NCT02842242Cardiomyopathy, Hypertrophic · United States | 2 | Completed | Bristol-Myers Squibb | Nov 2017 | 21 |
| NCT02480296Healthy · Australia | 1 | Completed | Bristol-Myers Squibb | Jul 2016 | 60 |
| NCT02356289Cardiomyopathy, Hypertrophic · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jul 2015 | 48 |
| NCT02329184Cardiomyopathy, Hypertrophic · United States | 1 | Completed | Bristol-Myers Squibb | Mar 2016 | 15 |
How it is read
Names in the registry
- “Mavacamten”, 11 entries
- “mavacamten”, 5 entries
- “MYK-461”, 4 entries
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 17 studies
- Anthrax, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.